Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -2.63
- Piotroski Score 2.00
- Grade Buy
- Symbol (ENLV)
- Company Enlivex Therapeutics Ltd.
- Price $0.91
- Changes Percentage (8.2%)
- Change $0.07
- Day Low $0.83
- Day High $0.92
- Year High $4.59
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 12/02/2024
- Fiscal Year End N/A
- Average Stock Price Target $15.00
- High Stock Price Target $15.00
- Low Stock Price Target $15.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.56
- Trailing P/E Ratio -0.86
- Forward P/E Ratio -0.86
- P/E Growth -0.86
- Net Income $-29,068,000
